Hepion Pharmaceuticals (HEPA) director purchases 500K shares and 500K warrants
Rhea-AI Filing Summary
Hepion Pharmaceuticals, Inc. director Gary S. Stetz II reported net purchases on August 3, 2026. He acquired 500,000 shares of Common Stock at a price of $0.05 per share, bringing his direct Common Stock holdings to 500,000 shares. He also acquired warrants for 500,000 shares of Common Stock with an exercise price of $0.06 and an expiration date of August 3, 2031, resulting in 500,000 warrants held directly. The Rule 10b5-1 checkbox was not marked, indicating these purchases were not reported as made under a trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 500,000 shares
Net Buy
2 txns
Insider
Stetz Gary S. II
Role
Director
Bought
1,000,000 shs ($25K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Warrants | 500,000 | $0.00 | $0.00 |
| Purchase | Common Stock | 500,000 | $0.05 | $25K |
Holdings After Transaction:
Warrants — 500,000 shares (Direct);
Common Stock — 500,000 shares (Direct)
Key Figures
Common Stock purchased: 500,000 shares
Purchase price per Common share: $0.05 per share
Warrants acquired: 500,000 warrants
+4 more
7 metrics
Common Stock purchased
500,000 shares
Shares of Common Stock purchased on August 3, 2026
Purchase price per Common share
$0.05 per share
Price paid for Common Stock on August 3, 2026
Warrants acquired
500,000 warrants
Warrants to acquire Common Stock, acquired August 3, 2026
Warrant exercise price
$0.06 per share
Exercise price for warrants exercisable into Common Stock
Warrant expiration
August 3, 2031
Expiration date of warrants acquired on August 3, 2026
Common shares held after
500,000 shares
Total Common Stock directly held following the transaction
Warrants held after
500,000 warrants
Total warrants directly held following the transaction
Key Terms
Warrants, exercise price, expiration date, Rule 10b5-1
4 terms
Warrants financial
"The warrants give the right to purchase 500,000 shares of Common Stock"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
exercise price financial
"warrants for 500,000 shares of Common Stock with an exercise price of $0.06"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"an exercise price of $0.06 and an expiration date of August 3, 2031"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Rule 10b5-1 regulatory
"The Rule 10b5-1 checkbox was not marked, indicating no trading plan"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
FAQ
What did Hepion Pharmaceuticals (HEPA) director Gary S. Stetz II buy on August 3, 2026?
Gary S. Stetz II purchased 500,000 shares of Common Stock of Hepion Pharmaceuticals at $0.05 per share and acquired warrants for 500,000 shares of Common Stock exercisable at $0.06 per share.
What are the key terms of the warrants acquired by the HEPA director?
The warrants give the right to purchase 500,000 shares of Hepion Pharmaceuticals Common Stock at an exercise price of $0.06 per share, with an expiration date of August 3, 2031, and are held directly by the reporting person.
Were the HEPA insider’s August 3, 2026 transactions under a Rule 10b5-1 plan?
No. The Form 4’s Rule 10b5-1 checkbox was not checked, indicating the reported purchases of Common Stock and warrants were not reported as executed pursuant to a Rule 10b5-1 trading plan.
What is the total number of HEPA securities the director bought in this Form 4 filing?
In total, the director acquired 1,000,000 HEPA-related securities: 500,000 shares of Common Stock at $0.05 per share and 500,000 warrants exercisable into Common Stock at an exercise price of $0.06 per share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
